Lung Cancer Clinical Trial
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.
Age ≥ 18
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Weight ≥ 35 kg
Diagnosed with histologically or cytologically confirmed locally advanced/metastatic NSCLC with EGFRm
For Arm A (Oleclumab + Osimertinib arms): must have received 1 prior line of therapy with an EGFR tyrosine kinase inhibitor (TKI) and confirmed T790M negative
For Arm B (Oleclumab + AZD4635 arms): must have received at least 2 but not more than 4 prior lines of therapy.
Receipt of an EGFR TKI within 14 days of the first dose of study treatment
Receipt of any conventional or investigational anticancer therapy not otherwise specified within 21 days of the planned first dose
Prior receipt of any investigational immunotherapy. Participants may have received agents that have local health authority approval for the disease indication
Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed.
Participants with a history of venous thrombosis within the past 3 months
Participants with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 6 months
Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment
Other invasive malignancy within 2 years
Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression
Current or prior use of immunosuppressive medication within 14 days prior to the first dose
Additional Exclusion Criteria for Arm A
Concurrent treatment (or inability to stop therapy) with medications or herbal supplements known to be potent inducers of cytochrome P (CYP) 3A4
Participants has a history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD
Participants requires continuous supplemental oxygen for any reason
Additional Exclusion Criteria for Arm B
Herbal preparations/medications are not allowed throughout the study
History of seizures excluding those that occurred due to previously untreated CNS metastasis
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 13 Locations for this study
La Jolla California, 92093, United States
San Francisco California, 94143, United States
Aurora Colorado, 80045, United States
New Haven Connecticut, 06510, United States
Atlanta Georgia, 30322, United States
Chicago Illinois, 60611, United States
Baltimore Maryland, 21224, United States
New York New York, 10032, United States
Houston Texas, 77030, United States
Seoul , 03080, Korea, Republic of
Seoul , 05505, Korea, Republic of
Seoul , 06351, Korea, Republic of
Taichung , 40705, Taiwan
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.